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Abstract
Over the past several years, employment of multifunctional polymeric excipients-based 
nanoparticles for controlled and targeted drug delivery of therapeutic modalities to 
mucosal membrane-based organelles and systemic circulation has gained enormous 
interest. Because they promise to resolve numerous key therapeutical issues associated 
with current clinical practice including low treatment efficacy and significant side effects. 
Potential controlled and targeted drug delivery systems, therefore, should be able to 
overcome not only extracellular barriers but also intracellular barriers. Extracellularly, 
targeted nanocarriers ought to provide extended circulation time, selective binding to 
the targeted mucosal tissues, long residence time at the site of absorption, and controlled 
drug release. Intracellularly, the targeted nanocarriers should offer cellular uptake, cellu-
lar localization, and endosomal release. Hence, this chapter will provide an overview of 
the unique chemistry of multifunctional polymeric enveloped diverse nanocarriers such 
as dendrimers, semiconducting polymer dots, quantum dots, carbon dots, and magnetic 
as versatile platform addressing both extracellular and intracellular barriers.
Keywords: polymeric nanocarriers, extracellular drug targeting, intracellular drug 
targeting, carbon dots, polymer dots, quantum dots, magnetic nanoparticles
1. Introduction
Targeted drug delivery has been massively investigated because of their potential to overcome 
hurdles of conventional therapy [1]. Administration of drug selectively at desired site ensures 
the maximum amount of drug to be available at that locality. Moreover, lesser absorption of 
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drug systemically minimizes the potential for unwanted effects. To target a drug so that it 
may avoid its uptake by off target tissues or cell and allow its residence at desired site for lon-
ger period of time, it is usually escorted with some targeting agent. These targeting molecules 
can be receptor-specific ligands, vehicles, or biological molecules [2].
Nanocarriers have revolutionized therapeutic approaches by providing numerous means for 
drug targeting. Nanocarriers have employed various approaches to target drug to a specific 
organ, tissue, cell, or organelle. The therapeutic efficacy of these carrier systems is highly 
dependent on their entry into target sites. It has been studied that passage of particles across 
endothelial cells requires their size to be less than 100 nm approximately [3]. This limits the 
greater-sized particles to extravagate into tissues having compromised endothelial arrange-
ment. Nanostructures with hydrophobic outer surface have been observed to undergo phago-
cytosis after being opsonized [4].
Various polymers with diverse chemical nature and various activities and characteristics have 
been explored to design nanocarriers for delivery of drug molecules. Among them, biode-
gradable polymers have been of particular interest. Both natural and synthetic biodegradable 
polymers have been exploited to functionalize nanoparticles exploiting diverse approaches 
to deliver drug in an effective manner to its target site [1]. Such functionalized polymeric 
nanostructures (also known as multiplex nanoparticles) have been widely investigated as an 
effective carrier for a wide variety of drugs as well as biological molecules such as DNA and 
proteins [1]. Current research has been precisely focused on the use of biodegradable poly-
mers that have shown great promise in modifying the delivery of drug as well as tissue engi-
neering. Such polymers have shown to provide extended and targeted drug release for days 
to weeks as well as shown great promise for intracellular transport of drugs [5].
Various treatment modalities require intracellular delivery of drug as the causative agent is 
harboring within cell. This is the case commonly associated with infectious diseases such 
as tuberculosis, leishmaniasis, and leprosy, where the pathogen invades macrophages. 
Therefore, complete eradication requires utmost delivery of drug at right concentration to 
infected cells. Certain other conditions also require delivery of therapeutic agents into cyto-
plasm where they can target various cellular organelles such as endoplasmic reticulum, mito-
chondria, nucleus, and lysosomes [6]. This has found particular interest in gene therapy for 
targeting cellular genome [7] as well as drug targeting for the treatment of cancer and lyso-
somal storage disease [6]. Intracellular transport has also been widely appreciated for bioim-
aging and biosensing both in vitro and in vivo.
2. Intracellular drug targeting
Entry or transport of drug into the cell has never been easy and thus widely explored [6]. 
Cells offer several mechanisms to allow ingress of drug carriers prominently comprising 
endocytosis. Internalization of drug into cells may either obey receptor-dependent endocyto-
sis or receptor-independent pathway as shown in Figure 1. Combining small drug molecules 
with macromolecular carriers restricts their entry into highly perfused tissues, thus averting 
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untoward side effects [2]. Macromolecules (proteins, peptides, DNA, etc.) are not allowed by 
lipophilic biological membranes to enter into cytoplasm. Such molecules may follow active 
transport involving endocytosis via cell surface receptors [6]. This receptor-mediated endo-
cytosis offers a faster course for drug internalization in contrast to untargeted conjugates. 
These receptors have been located on surface of cells as well as accompany intracellular 
membranes [8].
2.1. Clathrin-associated, receptor-mediated endocytosis
The bases on which molecules are sorted to follow either clathrin-dependent or clathrin-inde-
pendent pay are still not fully understood. However, it has been found that some specialized 
lipid domains are involved in membrane organization, sorting, and signal transduction in 
clathrin-independent endocytosis [9]. Ligand-associated drug carriers may bind to specific 
cell receptors that get assembled into particular areas of plasma membrane termed as coated 
pits. These regions (diameter 0.1 μm approx.) have been explained as plasma membrane 
invaginations with fuzzy cytoplasmic coat. This coat is mainly composed of clathrin protein 
present at cytoplasmic periphery of membrane and serves as major route for cellular inter-
nalization [10] as depicted in Figure 2. These coated pits allow intracellular vesicle forma-
tion in less than 1 min of time that is much faster than other mechanisms of endocytosis. A 
protein known as adaptin is responsible for polymerization of clathrin in the form of polyhe-
dral lattice scaffold by binding with cell surface receptors. Two other proteins amphiphysin 
and endophilin get neighboring membrane into close vicinity. Dynamin (a cytosolic GTPase) 
gathers around the neckline of budding vesicle followed by its scission and intracellular 
discharge [2]. After intracellular entry of vesicle, an uncoating protein (heat shock protein; 
hsc70) causes the clathrin coat to shed of. At this stage, endocytosis trafficking of endosomal 
content decides the fate of therapeutic agent delivered. Endosomes may end up into lyso-
somes that may lead to degradation of drug or may be safely released into cytoplasm to reach 
desired organelle [6].
Figure 1. Pathways adopted for intracellular drug transport.
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2.2. Cell adhesion molecule (CAM)-mediated endocytosis
Drug targeting has also been investigated using cell adhesion molecules (CAMs). Recently, 
integrins and cadherins have been found to internalize their ligand into intracellular milieu. 
Thus, many cell adhesion peptides such as arginylglycylaspartic acid (RGD) [11] and pep-
tides derived from intercellular adhesion molecule 1 (ICAM-1) and lymphocyte function-
associated antigen 1 (LFA-1) sequences that bind to specific integrins have been extensively 
investigated for targeting tumor and vascular endothelial cells and suppressed progression 
of autoimmune disorders [12]. CAMs undergo cellular internalization while they are recycled 
via clathrin-coated pits and thus can be useful in cell-specific drug targeting through specific 
peptides. Such peptides are usually derived from proteins comprising extracellular matrix, 
immunoglobulins superfamily, and integrins. Integrins have also been associated with cellu-
lar uptake of certain viruses and bacteria through surface interactions at unique regions and 
initiate transduction pathways [13].
2.3. Caveolin-dependent, receptor-mediated endocytosis
Another version for cellular internalization of drug carriers is caveolin-mediated endocytosis. 
This process is sensitive to temperature and also dependent on ATP and sulphydral reagents 
[14]. Caveolin-1 is a protein associated with flask-shaped invaginations making up greater 
Figure 2. (A) Clathrin-dependent receptor-mediated endocytosis, I—entry of targeting drug carrier in clathrin-coated 
pits and binding with ligand-specific receptor; II—dynamin-associated endocytosis; III—formation of clathrin-coated 
vesicle; IV—shedding of clathrin coat; V—early endosomal sorting and uncoupling of ligand-receptor; VI-A—formation 
of late endosome; VI-B—formation of transport vesicle; VII—fusion of lysosome with transport vesicle; VIII—formation 
of endolysosome. (B) Caveolin-dependent, receptor-mediated endocytosis, I—interaction of ligand with receptor; 
II—movement of receptor ligand complex toward caveolar invagination; III—retention of receptor ligand complex in 
caveolar invagination; IV—dynamin-associated caveolar endocytosis; V—formation of caveosome; VI-A and VI-B—
transport of drug carrier to endoplasmic reticulum or Golgi apparatus, respectively. (C) Macropinocytosis, I—movement 
of drug carrier toward membrane ruffling; II—rearrangement of cytoskeleton, folding of ruffle around drug carrier; 
IV—internalization; V—formation of macropinosome; VI—early maturation of macropinosome; VII—late endosome; 
VIII—endolysosome.
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than 10% of endothelial cell membrane. Only cells expressing caveolin-1 protein develop 
caveolar invaginations [15]. Ligand after association with plasma membrane moves along it 
toward caveolar invagination, where being retained for some time internalization occurs via 
certain unidentified receptor as shown in Figure 2. The presence of GTPase dynamin has sug-
gested involvement of caveolae in membrane internalization [9].
Folic acid, cholesterol, albumin complexes, and serum lipoproteins are commonly encoun-
tered ligands internalized via caveolae-dependent endocytosis. These ligands have been 
considered as attractive candidates for drug targeting especially to intracellular organelles. 
Caveolar vesicles after getting internalized fuse with caveosomes following delivery of con-
tent at subcellular level bypassing acidic and degradative milieu of lysosomes [15]. Another 
mechanism suggested for caveolae-dependent internalization is ‘potocytosis’ that implies dif-
fusion of smaller moieties into cytoplasm after interacting caveolae without membrane inter-
nalization [16]. One other associated pathway for cells without caveolae expression is ‘lipid 
rafts’. These flat structures are composed of lipid- and protein-based assemblies that allow 
receptor-specific ligands to anchor on raft domain [15].
2.4. Macropinocytosis
Macropinocytosis employs distinct mechanism to transport molecules inside the cell without 
any direct coordination with receptors [17]. Macropinocytosis begins with actin polymeriza-
tion at surface of cell membrane that is regulated by tyrosine kinase, epidermal growth factor, 
and platelet-derived growth factor receptors. This leads to increased ruffling at membrane 
surface and subsequent formation of macropinosomes (Figure 2). It involves absorption of 
molecules present in extracellular fluid (ECF) and seems to be a slower process as compared 
to RME. This process has sometimes shown to accompany receptor-mediated endocytosis; 
thus, absorption of receptor bound ligand and molecules in ECF may occur through clathrin-
coated vesicles side by side. After entry of fluid vesicles, they are supposed to follow usual 
endolysosomal trafficking pathway [18]. Negative charge on membrane surface naturally 
favors positively charged molecules to reside there and eventually get internalized through 
fluid phase endocytosis. This phenomenon has been exploited by researches for intracellular 
delivery of drugs [19].
3. Extracellular drug targeting
Many targeting approaches utilize such mechanisms that exploit extracellular barriers to 
ensure efficient delivery of drugs. Nanocarriers following intravenous administration are rap-
idly recognized by reticuloendothelial system (liver and spleen macrophages), making it dif-
ficult for drug to reach its site of action at the minimum effective concentration [20]. This owes 
to opsonization of particle surface with certain plasma proteins (albumin, apolipoprotein-E, 
etc.) that make them recognizable by body’s immune system and thus are rapidly evacuated 
from circulation. Therefore, the extent of opsonization will determine the fate of nanoparticles 
in vivo [21].
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Recognition of nanoparticles by RES and their uptake by macrophages can be avoided by 
modifying surface properties of these carrier systems. One of such modifications is by mak-
ing surface of nanoparticles to be very hydrophilic. This avoids adsorption of opsonins and 
ensures nanoparticles to pass unrecognized by RES [22]. Surface of nanoparticles has been 
made more hydrophilic by increasing the thickness of coating layer of poloxamer and polox-
amine. Coating layers up to 10 nm were considered necessary to bypass RES [23].
Many drug molecules have shown poor penetration across the blood-brain barrier due to 
their inherent nature. These molecules have been successfully delivered to the brain when 
incorporated into nanocarriers [24]. Coated nanoparticles have been studied for delivery of 
drug into the brain. Polybutylcyanoacrylate (PBCA) nanoparticles coated with polysorbate-80 
have been studied to improve penetration of drug across the blood-brain barrier [25]. In a 
study, transport of nanoparticles across BBB was investigated. Penetration of nanoparticles 
across BBB was three to four times increased when charged nanoparticles were coated with 
dipalmitoyl phosphatidyl choline and cholesterol-based lipid bilayer [26]. Multifunctional 
nanoparticles have also been investigated for delivery of proteins and peptides. These bio-
logical molecules are associated with rapid degradation at acidic pH of GIT and by activity of 
proteolytic enzymes that owe to their shorter half-life. Moreover, lesser partition coefficient 
and diffusivity make their movement difficult across biological membranes. These limitations 
can be conquered using functionalized polymeric nanoparticulate drug delivery systems [27]. 
Properties of PLGA matrices have been modified through hydrogel systems to deliver pro-
teins and peptides. Bovine serum albumin was loaded in poly vinyl alcohol nanoparticles, 
which were then incorporated into PLGA microspheres and characterized to release the pro-
tein for more than 2 months [28]. Poly(isobutyl cyanoacrylate) nanocapsules have also been 
investigated for oral delivery of insulin [29].
Sustained release of drugs has also been achieved using various functionalized nanocarri-
ers. Poly DL-lactic acid (PLA) nanoparticles have been used to provide sustained release 
of savoxepine following intramuscular and intravenous administrations [30]. Damge and 
his coworkers have successfully developed nanocapsules for sustained delivery of insu-
lin. About 100 U/kg of insulin-loaded nanocapsules were effective to reduce blood glucose 
level for 6 days by 25% on oral administration to diabetic rats [31]. Colloidal suspension 
of docetaxel-loaded nanospheres has been prepared using PLA and PLGA to study sus-
tained release of drug after intravenous administration [32]. PEG-grafted polyamidoamine 
(PAMAM) dendrimers were used to control the release of adriamycin and methotrexate [33]. 
Mu and Feng have used d-α-tocopheryl polyethylene glycol 1000 succinate (TPGS) to pre-
pare controlled release paclitaxel nanoparticles with high encapsulation efficiency [34].
4. Nanocarriers for intracellular and extracellular targeting
Scientists have extensively explored a wide range of drug carriers at nanoscale extending 
from highly simple to complex geometries. Other than polymeric nanostructures, several 
lipids-based structures have been investigated for drug delivery, among which liposomes 
hold a noticeable status. Owing to their resemblance to lipid bilayer structure, they have been 
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studied for a wide range of therapeutic applications (antivirals, antimicrobials, antitubercu-
lar drugs, biological molecules, and gene therapeutics) by offering enhanced accumulation 
and reduced toxicity at targeted site. However, reduced stability and trouble in immobili-
zation of vector molecules on exterior of liposomes have led to exploration of other more 
useful nanocarriers [35]. Nanodots have exhibited great promise in therapeutics owing to 
diverse physicochemical properties, functionalization opportunities, and contenting stability 
attributes, which make them excellent candidate for bioimaging along with drug delivery. 
They have also been found substantially successful in photodynamic therapy in treatment 
of tumors [36]. Further, our discussion will be focused on multifunctional polymeric nano-
carriers including dendrimers, various nanodot structures, and magnetic nanoparticles with 
reference to their application in intracellular and extracellular targeting for diagnostics and 
therapeutics.
4.1. Dendrimers
Dendrimers are three-dimensional, globular structures consisting of highly branched, repeat-
ing, and controllable peripheral functionalities originating from a central core [37]. These 
structures are assembled in layered fashion from core by repetition of two sequential reac-
tion steps. Origination of a new branching point in layer leads to creation of a new genera-
tion (denoted as G). Thus, a regular dendrimer structure is usually composed of three major 
elements, i.e., a central core, branched units, and surface groups [38]. Such a diverse struc-
ture and nanometric size range has pulled them to massive exploration as potential carrier 
for drug delivery to targeted regions. The chemistry of dendrimers offers several modes for 
incorporation of drugs. Most commonly, drug is linked either covalently or noncovalently to 
dendrimers. A drug can be noncovalently introduced into dendrimer by simple encapsulation 
method that is mostly used to enhance solubilization of lipophilic drugs in aqueous media. 
Charged drugs such as DNA, RNA, or siRNA can also be incorporated into dendrimers 
through noncovalent electrostatic interactions. Thus, drug can be conjugated in this manner 
to both the internal and external regions of dendrimer. Covalent incorporation involves for-
mation of stable bonds between drug and dendrimers [39].
Recent research is focused on development of synthetic carriers for delivery of genetic mate-
rial with low cytotoxicity, highly efficient delivery, and minimal lysosomal degradation [40]. 
Gene delivery using polyamidoamine (PAMAM) dendrimers has been studied by Haensler 
and Szoka. Covalent linking of dendrimer with GALA peptide resulted in improved trans-
fection efficiency [41]. Polypropylene imine (PPI) dendrimers enjoying low generations have 
also shown capacity as DNA carrier for gene transfection with lower cytotoxic potential [42]. 
Dendrimers have also been explored for delivery of chemotherapeutic agents. Quintana 
and coworkers have developed PAMAM dendrimers composed of ethylenediamine core. 
Methotrexate along with targeting ligand and fluorescein was covalently attached to dendritic 
surface. Experimental data confirmed highly specific binding with KB cell line with 100% 
improved cytotoxic response as compared to free drug [43]. In another study, siRNA was 
incorporated in PPI dendrimer that was stabilized using cross-linker to cage the preformed 
siRNA-dendrimer nanoparticle. PEG layer was applied over this nanostructure that further 
utilized luteinizing hormone releasing hormone (LHRH) to guide siRNA-loaded nanoparticles 
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to tumor cells. In-vivo studies suggested highly specific tumor targeting with improved accu-
mulation of siRNA in cytoplasm of cells and effective gene silencing [44].
Dendritic structures have also inspired boron neutron capture therapy for tumor targeting. 
To kill tumor cells, it is necessary for 10B to reach intracellular concentration of at least 
109 atoms/cell. This tumor-specific delivery at desired concentrations has been achieved 
through use of boronated antibodies. Epidermal growth factor receptors (EGFR) that are 
overexpressed at surface of glioma cells have been targeted by 10B PAMAM dendrimers. 
Dendrimers after being covalently linked to epidermal growth factor were effectively inter-
nalized by endocytosis with substantial accumulation of 10B in lysosomes of cells in vitro [45]. 
However, in-vivo studies demonstrated uptake of boron carriers by the liver and less level of 
accumulation in C6 glioma cells. To address uptake of boronated dendritic conjugates by the 
liver, scientists have exploited the steric effect provided by polyethylene oxide (PEO) chains. 
Such PEO-shielded boronated PAMAM dendrimers showed lesser uptake of conjugate by 
the liver. However, uptake of PEO-shielded dendritic conjugates by liver was increased with 
an increase in the number of PEO chains [46].
Exploration of dendrimers in photodynamic therapy (PDT) has also captured great interest. 
Therapy employs a photosensitizing agent that upon exposure to light of specific wavelength 
causes irreversible photo-chemical or photo-biological damage to tumor cells. Dendrimers on 
suitable peripheral functionalization can be promising carrier for photosensitizers. Eighteen 
ALA (5-aminolevulinic acid) units have been conjugated with dendrimer through amide link-
age. These ALA-conjugated dendrimers exhibited increased cellular level of protoporphyrin 
IX (PIX) and thus showed increased cytotoxicity on exposure of radiations in PAM 212 tumori-
genic cell lines [47]. Because of increased tissue permeability to near IR or IR light, the photo-
dynamic system with high absorbance at longer wavelength is extremely attractive. To exploit 
this feature, aluminum-phthalocyanines polymer conjugates have been designed with the 
maximum absorption observed at 675 nm [48]. A two-photon approach also has great potential 
to target deeper tissues with near IR laser. Multivalent character of dendrimers has the capac-
ity to accommodate several two-photon absorbing moieties to porphyrin core. Excitation of 
chromophores at 780 nm resulted in generation of increased singlet oxygen luminescence [49].
4.2. Semiconductor polymer dots
Semiconducting polymer dots (Pdots), also described as organic nanodots or conjugated 
polymeric nanoparticles (CPNs), have emerged as promising fluorescent probes due to their 
exceptional brightness, high quantum yield, nonblinking, photo-stability, and faster emis-
sion rate. Pdots, particularly, refer to small semiconducting polymeric nanoparticles and 
have shown remarkable conduction properties due to the presence of highly delocalized 
π-conjugated backbone [50]. Pdots prepared by miniemulsion method usually produced 
polymeric particles with size ranging from 40 to 500 nm depending on nature of polymer 
and concentration of surfactant. Reprecipitation method yields Pdots in the range of 5–30 nm. 
Size usually can be modified depending on biological application; however, most bioimag-
ing and assays require smaller nanoparticle. Brightness and photo-stability of fluorescent 
Pdots appear to increase with size increment but have also exhibited higher steric hindrance, 
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decreasing their target specificity and binding affinity [51]. These carriers have widely inves-
tigated for their outstanding potential for bioimaging and biosensing both in vitro and in vivo. 
Major advantage lies in lesser cytotoxicity as was observed in the case of inorganic nanocrys-
tals or quantum dots (Qdots) that were also observed to be associated with genotoxic and 
epigenetic effects in mammalian cells even at minute concentrations [52].
Biological applications of fluorescent probes can be controlled by manipulating surface chem-
istry. Usually, aqueous solubility is the primary requirement for these particles to perform 
biological functions efficiently. Such modifications have been carried out by incorporat-
ing charged molecules in polymer side chains [53]. Current research has much interest in 
development of various multifunctional Pdots that offer a wide range of biological appli-
cations due to easy preparation and diverse chemical dynamics. Conjugated polymers on 
the basis of varying structure of backbone can be distinguished into four major categories 
including poly-(fluorine), poly-(p-phenylene vinylene), poly-(p-phenylene ethynylene), and 
poly-(thiophene). These polymeric backbones can be further functionalized to incorporate 
desired characteristics [54]. Wang and coworkers have developed water-soluble conjugated 
polymer (polythiophene) with tyrosin kinase inhibitor (lapatinib)-modified side chains for 
plasma membrane imaging by targeting intracellular regions of transmembrane proteins [55]. 
Scientists have prepared conjugated polymer nanoparticles for both drug delivery and cell 
imaging together via exploiting electrostatic interactions among cationic conjugated polymers 
and anionic functionalities. Doxorubicin was delivered to target cancer cells by conjugating 
it with cationic fluorescent PFO and anionic poly-(l-glutamic acid) that allowed to monitor 
drug release through ‘turn on’ fluorescent signal generated by PFO [56].
Apart from cellular imaging, Pdots have also been investigated for delivery of DNA and 
siRNA. It has been found that nucleic acid carrying a negative charge can be easily incorpo-
rated into positively charged semiconductor Pdots. Silva and coworkers have demonstrated 
the delivery of siRNA using fluorescent CPNs for posttranscriptional gene silencing in plant 
protoplast without any significant impact on cellular viability in 72 h. They also explained the 
delivery of siRNA to specifically targeted genes in NTCesA-1 pathway associated with cel-
lulose biosynthesis using CPNs [57]. Moon and associates have developed loosely aggregated 
CPNs for delivery of siRNA for transfection into HELA cells. siRNA-loaded CPNs caused 
downregulation of actin b protein with a transfection efficiency of 94% [58].
Scientists have also investigated the role of conjugated polymers for their antimicrobial poten-
tial. Cationic, light-absorbing, conjugated polyelectrolytes were studied for their activity 
against Gram-positive bacterial spores and Gram-negative bacterial strains. The study sug-
gested that conjugated poly-electrolytes formed surface coating on both bacterial types and 
caused light-induced bactericidal activity [59]. Electrostatic interactions between negatively 
charged cell surfaces and oppositely charged markers have also been exploited against micro-
bial and cancerous cells. Cationic CPNs have been designed through electrostatic interaction 
between positively charged PBF and negatively charged SDPA (disodium salt 3,3′-dithiodi-
propionic acid). These nanoparticles on photoexcitation by white light sensitized production 
of reactive oxygen species that effectively killed surrounding tumor and bacterial cells along 
with fluorescent imaging of cellular uptake of these particles [60]. Electrostatic interactions 
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have also been exploited for delivery of doxorubicin through multifunctional CPNs. CPNs 
(50 nm approx.) with excellent photo-stability and quantum yield but lower cytotoxicity have 
been prepared by combination of cationic PFO and anionic poly(l-glutamic acid) followed 
by conjugation with doxorubicin. This carrier offered targeted release of drug in cancer cells 
along with concurrent examination of drug release via self-luminescence activity [56].
4.3. Carbon dots
Carbon dots (CDs), also known as carbon nanoparticles or carbon quantum dots, are quasi-
spherical fluorescent nanoparticles, gaining excessive attention because of unique optical 
nature, biocompatibility, low cytotoxicity, and simplistic synthesis [61]. These particles were 
accidently discovered while electrophoretic purification of single-walled carbon nanotubes 
(SWCNTs) synthesized using arc discharge process. CDs are usually defined as zero-dimen-
sional particles with size range lying around 10 nm. Various synthetic approaches have been 
investigated for preparation of CDs with efficient photoluminescence, longer wavelength, and 
multicolor tunable emission [62]. Several types of carbon materials have been engaged to pre-
pare CDs including graphite, activated carbon, carbon nanotubes (CNTs), and nano-diamond 
using top-down approach [63]. Bottom-up approach has employed citrate, biomolecules, and 
polymer-silica nanocomposites to prepare CDs using a variety of reaction conditions [64]. 
CDs have been addressed as safe and biocompatible substitutes to quantum dots that offer 
better brightness, photo-stability, and lower cytotoxicity both in vitro and in vivo [65].
Fluorescent CDs have expressed great potential in the field of biosensing, imaging, and pho-
todynamic therapy as well as gene and drug delivery. CDs can be employed for in-vitro and 
in-vivo cell imaging using both one- and two-photon excitations. Yang and coworkers have 
demonstrated biomolecule surface-modified fluorescent carbon dots for in-vivo cell imaging 
along with good biocompatibility and less cytotoxicity [66]. Fluorescent CDs with surface 
modified with PEG were also studied for in-vivo biocompatibility and cytotoxicity through 
fluorescence imaging [67]. Luo and coworkers have extensively reviewed the optical imaging 
of carbon dots both in vitro and in vivo [65]. Various functionalized CDs have been studied for 
fluorescent imaging of plasma membrane and cytoplasm of COS7 cells, BGC823 cells, MG-63 
cells, A549 cells, and HEPG-2 cells [68]. Scientists have also demonstrated uptake of CDs by 
endosomes and lysosomes in fluorescent imaging of HELA cells [69]. Besides these investiga-
tions, some studies have reported distribution of CDs in entire cell including nucleus [70]. 
CDs have also been explored for cellular imaging and labeling of E. coli [63].
CDs have also been investigated as biosensors in various research studies. Fluorescent car-
bon dots when conjugated with N-(2-aminoethyl)-N, N, N-tris (pyridin-2-yl methyl) ethane-1, 
2-diamine have been studied to detect intracellular Cu+2 ions with greater specificity and 
stability [71]. In another study, fluorescent CDs have been used for detection of metal ions. 
Scientists have prepared carbon dots from citric acid as a carbon source in the presence of PEI 
for intracellular imaging and detection of Cu+2 ions [72]. Besides metal ion detection, COOH- 
or OH-functionalized CDs have been used as a receptor to detect change in hydrogen ion con-
centration. This fluorescent C dot probe has been successfully investigated to detect change 
in pH of 6–8 range in A549 and LLC-MK2 cells [73]. CDs have been studied for detection of 
glucose as its transport is associated with certain anomalies such as diabetes and cancer [74].
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Scientists have also demonstrated use of CDs for detection of DNA. ssDNA was immobilized 
on CDs that can get hybridized with required complementary DNA molecule to form dsDNA 
followed by desorption from CDs and quantification of fluorescence [75]. CDs-dsDNA com-
plex has also been investigated to detect histones. The strong interaction between DNA and 
histone causing the detachment of DNA from CD that turned on the signal for native fluores-
cence of CD [76]. CDs conjugated with gold and silver nanostructures have been explored as 
electro-chemiluminescence (ECL) immuno-sensing devices for detection of prostate-specific 
antigen (PSA) [77]. CDs have also been conjugated with chlorin e6 (Ce6) photosensitizer for 
efficient intracellular transport of photosensitizer, longer circulation time, and homing ability 
in tumor cells. These conjugates revealed excellent stability, biocompatibility with least cyto-
toxicity and exhibited tremendous bioimaging and homing ability in subcutaneous MGC-803 
xenografts in nude mice [78].
Another therapeutic application associated with CDs is gene and drug delivery to targeted 
cells. pH-responsive, COOH-functionalized CDs caped on surface of mesoporous silica 
nanoparticles (MSPs) have been studied for intracellular tracking and delivery of doxorubicin 
with strong luminescence and low cytotoxicity both in vitro and in vivo [79]. CDs-conjugated 
mesoporous silica nanoparticles capped with PEG have been investigate for tracking con-
trolled release of doxorubicin through quantifiable fluorescent intensity in HELA cells [80]. In 
another study, hollow CDs have been prepared from bovine serum albumin for pH-depen-
dent delivery of doxorubicin and its rapid intracellular uptake. Such functionalized hollow 
CDs have been regarded suitable for bioimaging and targeted drug delivery [81]. Quinolone-
conjugated fluorescent CDs have also been explored for in-vitro cellular imaging and delivery 
of drug to cancer cells [82].
4.4. Quantum dots
Quantum dots (Qdots) are inorganic, semiconductor, fluorescent nanostructures composed 
of II–IV or III–V group elements. They are crystal structures with size smaller than excitation 
Bohr radius (few nanometers), and these physical dimensions are controllable by time, tem-
perature, and molecules (ligands) used in their synthesis [83]. Qdots in the range of 2–6 nm 
are of especial interest due to resemblance of their dimensions with biomolecules and have 
also shown to display strong dimension-dependent electrical and optical characters. Other 
distinct features include necessity of few Qdots to generate a detectable signal and minimal 
photo-bleaching property [84]. The idea of quantum confinement is responsible for unique 
optical and electronic characteristic of Qdots. Both group II–IV and III–V Qdots have been 
synthesized with relatively lower quantum yield and greater size difference. Higher quantum 
yield and better luminescence were observed when CdSe core was capped on surface with 
ZnS or CdS (higher band gap) [85].
The optical character of Qdots has been associated with the interactions among electrons, 
holes, and surrounding environment. Qdots undergo absorption of photon when excitation 
energy surpasses band gap where electrons jump from valence band toward conduction 
band. The presence of multiple electronic states at elevated energy level offers excitation 
at relatively lower wavelengths across UV-visible spectra. Emission wavelength can be 
tuned among the region of blue and near infrared (NIR) wavelength by manipulating size 
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and composition of Qdots. This feature allows simultaneous excitation of multicolor Qdots 
with single light source that makes them excellent candidate for biological application. 
Bioconjugation and functionalization of Qdots have increased the spectrum of their activi-
ties [36]. Qdots have been widely investigated for in-vitro and in-vivo imaging at molec-
ular and cellular levels, to study intracellular trafficking as well as tumor targeting [86]. 
Quantum dots have been studied in immunofluorescence assays for detection of biological 
molecules and labeling of tissues and cells. NIR fluorescent nanoprobes conjugated with 
copolymer grafts of poly(l-lysine) and methoxy-polyethylene glycol succinate for in-vivo 
imaging of tumor related lysosomal protease activity. These probes successfully detected 
small-sized solid tumors with higher NIR signals and to examine specific enzyme activ-
ity [87]. Qdots have also explored to study the modifications in erythrocyte membranes 
caused by plasmodium invasion in malaria via immuno-cytochemical studies [88]. Jaiswal 
and coworkers have demonstrated multicolor imaging of Qdots-labeled live cells. They 
explained two approaches for cell labeling; either through intracellular uptake of Qdots by 
endocytic mechanism or use of antibody-conjugated quantum dots specific to cell surface 
proteins [89]. Parak and associates have used colloidal Qdots to study metastatic poten-
tial of cancer cells due to their photochemical stable nature and to study the mechanism 
of motility and migration of cancer cells. Uptake of nanocrystals was explained to occur 
through pinocytosis and phagocytosis [90].
Qdots have also been explored to prevent their nonspecific uptake by RES. Molecular 
markers expressed by blood vessels have been exploited to target nanocarriers toward 
specific tissues or organs. This strategy has been employed to target lung tumor cells using 
functionalized Qdots in mice [91]. Surface of quantum dots has been functionalized with 
COOH, NH2, and streptavidin that was further derivitized using PEG. PEG-conjugated 
Qdots decreased nonspecific uptake by RES, while COOH- and NH2-functionalized Qdots 
without PEG showed improved intracellular uptake among various cell types [92]. Qdots 
have also been explored for gene delivery and gene silencing. Sponge proton-coated 
Qdot-siRNA has been studied to improve gene silencing efficiency and reduced cyto-
toxicity in MDA-MB231 cells. These nanocarriers also allowed intracellular tracking and 
localization of siRNA delivery and transfection [93]. In another study, siRNA transfection 
was performed using Qdots. siRNA-Qdots exhibited greater photo-stability and tunable 
optical characteristics. This method was developed to observe the function of T-cadherin 
in intercellular communication [94].
Chitosan-folate-encapsulated ZnO Qdots have been prepared for delivery of anticancer 
agent doxorubicin with enhanced and longer photo-stability of Qdots. This nanocarrier 
showed an initial rapid release followed by controlled liberation of drug [95]. Doxorubicin-
loaded, immuno-liposome-based quantum dots were modified with HER2scFv for targeted 
delivery of drug to SKB-3 and MCF-7 cells with overexpressed HER2. These Qdot-IL con-
jugates exhibited receptor-dependent endocytosis in target cells but not in control MFC-7 
cells. They also showed longer circulation of Qdots, and their localization in tumor models 
was confirmed by florescence imaging [96]. Cadmium telluride-incorporated Qdots with 
PEI functionalization for tracking of plasmid DNA in mice were designed. After intrave-
nous injection, these structures showed rapid accumulation in the lungs, spleen, and liver. 
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PEG functionalization caused improved circulation time and rapid accumulation in cancer 
cells [97].
4.5. Magnetic nanocarriers
Magnetic nanoparticles (MNPs) are one of other fascinating elements of nanotechnology. 
Their nanometric dimension, biocompatibility, nontoxicity, and surplus accumulation in 
targeted cells or tissues justify intensive research in this subject matter. MNPs are mostly 
composed of ferromagnetic material such as ferrous or ferric oxide core with limited use of 
cobalt and nickel [98]. Magnetic properties are associated with movement of subatomic parti-
cles including electrons, holes, protons, and positive-/negative-charged ions. These materials 
respond to external stimulus of magnetic field and orient themselves according to magnetic 
moment. This magnetic behavior has been exploited for both in-vitro and in-vivo biomedical 
applications [99]. Magnetic nanoparticles have also been suggested for labeling cells in tis-
sue engineering as they can be easily handled using magnets. Streptavidin-functionalized 
paramagnetic particles in combination with antibodies have been investigated for magnetic 
field-guided retroviral infection in vitro [100].
Magnetic nanoparticles have the ability to cause ablation of tumor cells via generation of 
heat. AC magnetic field causes the magnetic particles dispersed in target cells or tissues to 
get heated. This heat is rapidly disseminated to diseased cells, and if 42°C (therapeutic tem-
perature threshold) can be maintained for 30 min, tumor cells get destroyed. However, this 
thermal ablation may be associated with undesirable concurrent killing of healthy cells [101]. 
Hase and coworkers have used ferromagnetic heating in combination of hepatic arterial 
embolization to study heat induction of ferromagnetic implants on VX2 hepatic cancer in rab-
bits. Results indicated extensive degeneration of tumor cells suggesting a suitable therapeutic 
strategy for localized hepatic carcinomas with little damage to healthy parenchyma of the 
liver because of selective heat induction [102].
Various functionalized magnetic nanocarriers have been investigated for targeted delivery 
of therapeutic agents. Magnetic drug carriers were designed either by using a magnetic 
core with surface coated with polymer or magnetic particles precipitated within porous 
polymeric composite. Such modifications have been studied to protect magnetic particle 
from harsh physiological vicinity and also to guide the drug carrier to desired location. 
Magnetic field-guided uncharged magnetic nanoparticles have been investigated for intra-
cerebral targeting of rat glioma-2 in male (Fisher 344) rats. These magnetic nanoparticles 
(10–20 nm) exhibited greater uptake in brain tumor cells as compared to larger size (1 μm) 
magnetic particles [103]. In another study, iron oxide core was coated with oleic acid and 
subsequent coat of PEG-oleic acid for sustained release of doxorubicin and as MRI con-
trast. These modified magnetic nanoparticles were further conjugated with antibodies for 
active targeting of MFC-7 cells. These MNPs showed better MRI contrast with longer circu-
lation time. They exhibited sustained release of drug with enhanced antiproliferative effect 
[104]. Doxorubicin-loaded monodisperse mesoporous single crystal iron oxide nanopar-
ticles have also been developed as a promising carrier with improved drug loading and 
delivery [105].




Multifunctional nanocarriers offer a wide spectrum of biological applications exploiting both 
extracellular and intracellular barriers. These polymeric nanostructures have successfully 
improved the efficacy and safety of molecules delivered for various diagnostic and therapeutic 
purposes. Such nanocarriers have propounded unique physicochemical properties that have 
overall augmented the pharmacokinetic and pharmacodynamics parameters of drugs owing 
to versatility in their dimensions and surface functionalization. Bioavailability of many drug 
molecules that was compromised due to uptake by RES has been enhanced by exploiting these 
nanodevices. They have also offered long circulation time with release of drug molecules in 
a controlled or sustained manner with substantially fewer adverse effects. Nanocarriers have 
also shown exceptional promise in cellular imaging and diagnosis. By using various function-
alization techniques, fluorescent probes have been directed to target tissues and cells to study 
site-specific delivery as well as intracellular trafficking of targeted molecules. Thus, they have 
been exploited to perform dual role of cell imaging along with drug delivery. Nanocarriers 
have also been successfully employed for gene transfection and gene silencing as well as in-
vitro and in-vivo detection of biological molecules. Most recent therapeutic strategies under 
research seem substantially captivated in various dot structures for improved delivery of 
therapeutic agents, and the same is the case for magnetic nanoparticles that also have offered 
incredibly assuring results. However, much work is yet to be accomplished to prepare a suc-
cessful commercial candidate with an ultimate therapeutic spectrum. Critical in-vivo cytotoxic 
behavior of these nanocarriers and untoward effects on normal physiological processes still 
requires intensive exploration. Some drug-loaded coated nanoparticles have been subjected 
to preliminary human trials after display of promising outcomes in animal studies but will 
even so require a long while for appearance in clinical market.
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